Vivek Subbiah: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on LinkedIn:
“Delighted to host a JAMA Oncology podcast on Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
Tune in for a Sunday morning drive and listen to my interview with Dr. Katrina A. B. Goddard, lead author of the paper published in JAMA Oncology.
Listen on Spotify or Apple Podcasts or wherever you get your podcasts, or via this link below American Medical Association Ed Hub.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
More posts featuring Vivek Subbiah.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023